Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Eric Arnoult"'
Autor:
Dirk Roymans, Sarhad S Alnajjar, Michael B Battles, Panchan Sitthicharoenchai, Polina Furmanova-Hollenstein, Peter Rigaux, Joke Van den Berg, Leen Kwanten, Marcia Van Ginderen, Nick Verheyen, Luc Vranckx, Steffen Jaensch, Eric Arnoult, Richard Voorzaat, Jack M. Gallup, Alejandro Larios-Mora, Marjolein Crabbe, Dymphy Huntjens, Pierre Raboisson, Johannes P. Langedijk, Mark R. Ackermann, Jason S McLellan, Sandrine Vendeville, Anil Koul
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-15 (2017)
Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in
Externí odkaz:
https://doaj.org/article/a53af0caadf64c108081ce0c70f541ee
Autor:
Eric P. Gillis, Kyle Parcella, Michael Bowsher, James H. Cook, Christiana Iwuagwu, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Haichang Huang, Lourdes Valera, Chunfu Wang, Kasia Kieltyka, Dawn D. Parker, Jean Simmermacher, Eric Arnoult, Robert T. Nolte, Liping Wang, John A. Bender, David B. Frennesson, Mark Saulnier, Alan Xiangdong Wang, Nicholas A. Meanwell, Makonen Belema, Umesh Hanumegowda, Susan Jenkins, Mark Krystal, John F. Kadow, Mark Cockett, Robert Fridell
Publikováno v:
Journal of Medicinal Chemistry. 66:1941-1954
Autor:
Eric Arnoult, Ivona Bakaj, Jenson Qi, Billy Breton, S. Paul Lee, Alessandro Pocai, Shuyuan Zhao, Marie-Laure Rives, Arturo Mancini, Nadia Swanson, Brian Rady, Mark R. Player
Publikováno v:
Molecular Pharmacology. 93:581-591
GPR40 is a clinically validated molecular target for the treatment of diabetes. Many GPR40 agonists have been identified to date, with the partial agonist fasiglifam (TAK-875) reaching phase III clinical trials before its development was terminated d
Autor:
Serge Pieters, David McGowan, Florence Herschke, Frederik Pauwels, Bart Stoops, Stefaan Last, Werner Embrechts, Annick Scholliers, Wendy Mostmans, Kris Van Dijck, Bertrand Van Schoubroeck, Tine Thoné, Dorien De Pooter, Gregory Fanning, Mari Luz Rosauro, Mourad Daoubi Khamlichi, Ioannis Houpis, Eric Arnoult, Tim H.M. Jonckers, Pierre Raboisson
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 28:711-719
The discovery of a novel series of highly potent quinazoline TLR 7/8 agonists is described. The synthesis and structure-activity relationship is presented. Structural requirements and optimization of this series toward TLR 7 selectivity afforded the
Autor:
Eric Arnoult, Meghan Hall, Monicah A. Otieno, Hui Huang, Tonya Martin, Jose Silva, Joe Gunnet, Jianying Liu, Yuanping Wang, Shuyuan Zhao, Sanath K. Meegalla, June Xu, Alessandro Pocai, Mark R. Player, Brian Rady, S. Paul Lee
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 28:720-726
Compound 12 is a GPR40 agonist that realizes the full magnitude of efficacy possible via GPR40 receptor agonism. In vitro and in vivo studies demonstrated superior glucose lowering by 12 compared to fasiglifam (TAK-875), in a glucose dependent manner
Autor:
Laurence Queguiner, Carlos Afonso, Jerome Guillemont, Eric Arnoult, David Speybrouck, Virginie Domalain, Marie Hubert-Roux, Dany Jeanne Dit Fouque
Publikováno v:
European Journal of Mass Spectrometry
European Journal of Mass Spectrometry, IM Publications, 2019, 25 (3), pp.291-299. ⟨10.1177/1469066718813226⟩
European Journal of Mass Spectrometry, IM Publications, 2019, 25 (3), pp.291-299. ⟨10.1177/1469066718813226⟩
International audience; Mycobacterium tuberculosis infection results in more than two million deaths per year and is the leading cause of mortality in people infected with HIV. A new structural class of antimycobacterials, the diarylquinolines, has b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::193463214cb8e11c02132a54dc59c707
https://hal-normandie-univ.archives-ouvertes.fr/hal-02330535
https://hal-normandie-univ.archives-ouvertes.fr/hal-02330535
Autor:
Kevin L. Grove, Celia Jenkinson, Songmao Zheng, Ranabir Sinharoy, James N. Leonard, Veronica Moreno, Mark D. Erion, Paul Kievit, Katharine D'Aquino, Wenying Jian, Rebecca Pick, Case Martin A, Lindsay Bader, Ronald V. Swanson, Lijuan Kang, Mark J. Macielag, Eric Arnoult, Yue Mei Zhang, Wilson Edwards, Ellen Chi, Annette Eckardt, Shamina M. Rangwala, Ann Lacombe
Summary The gut hormone PYY3–36 reduces food intake in humans and exhibits at least additive efficacy in combination with GLP-1. However, the utility of PYY analogs as anti-obesity agents has been severely limited by emesis and rapid proteolysis, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c46e7aca3f37ff4f08e5012c80f484
https://europepmc.org/articles/PMC6701930/
https://europepmc.org/articles/PMC6701930/
Autor:
Marie-Laure, Rives, Brian, Rady, Nadia, Swanson, Shuyuan, Zhao, Jenson, Qi, Eric, Arnoult, Ivona, Bakaj, Arturo, Mancini, Billy, Breton, S Paul, Lee, Mark R, Player, Alessandro, Pocai
Publikováno v:
Molecular pharmacology. 93(6)
GPR40 is a clinically validated molecular target for the treatment of diabetes. Many GPR40 agonists have been identified to date, with the partial agonist fasiglifam (TAK-875) reaching phase III clinical trials before its development was terminated d
Autor:
Monicah A. Otieno, Jose Silva, Eric Arnoult, Michael P. Winters, Hui Huang, Tonya Martin, Mark R. Player, Sanath K. Meegalla, Meghan Towers, Heng-Keang Lim, Jianying Liu, S. Paul Lee, Shuyuan Zhao, Alessandro Pocai, Fran Xu, Brian Rady
Publikováno v:
Bioorganicmedicinal chemistry letters. 28(3)
GPR40 partial agonism is a promising new mechanism for the treatment of type 2 diabetes mellitus with clinical proof of concept. Most of the GPR40 agonists in the literature have a carboxylic acid functional group, which may pose a risk for idiosyncr
Autor:
David McGowan, Florence Herschke, Frederik Pauwels, Bart Stoops, Stefaan Last, Serge Pieters, Annick Scholliers, Tine Thoné, Bertrand Van Schoubroeck, Dorien De Pooter, Wendy Mostmans, Mourad Daoubi Khamlichi, Werner Embrechts, Deborah Dhuyvetter, Ilham Smyej, Eric Arnoult, Samuël Demin, Herman Borghys, Gregory Fanning, Jaromir Vlach, Pierre Raboisson
Publikováno v:
Journal of medicinal chemistry. 59(17)
Toll-like receptor (TLR) 7 and 8 agonists can potentially be used in the treatment of viral infections and are particularly promising for chronic hepatitis B virus (HBV) infection. An internal screening effort identified a pyrimidine Toll-like recept